Alebund Pharmaceuticals

A biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases.

Launch date

2018

Employees

Market cap

Enterprise valuation

$688m (Public information from Apr 2023)

China (HQ)

http://www.alebund.com/

https://www.linkedin.com/company/alebund-pharmaceuticals/

Date	Investors	Amount	Round
-	Yuansheng BioVenture 3E Bioventures	N/A	-
Jan 2020	Lilly Asia Ventures Huagai Capital Med-Fine Capital	N/A	Series A
May 2021	Lilly Asia Ventures Quan Capital Sherpa Venture Partners Med-Fine Capital 3E Bioventures	$60.0m	Series B
Sep 2021	Morningside Group Lilly Asia Ventures Quan Capital Loyal Valley Capital YuanBio Venture Capital Sherpa Venture Partners Verition Fund Management 3H Health Investment Octagon Capital Advisors HT Capital 3E Bioventures	$54.5m Valuation: $300m	Series B
Apr 2023*	Lilly Asia Ventures Quan Capital Verition Fund Management 3H Health Investment Dingxin Capital Octagon Capital Advisors Jiangsu Dingxin Capital Management Yangzhou Longchuan Holding Group	CNY200m Valuation: CNY5.0b	Series C
Apr 2023*	N/A	CNY800m	Debt
Total Funding		$142m